NCT00784147已完成2 期
A Phase 2b, Randomized, Double-Blinded, 48-Week, Multicenter, Dose-Response Study of Ibalizumab Plus an Optimized Background Regimen in Treatment-Experienced Patients Infected With HIV-1(Amended to 24-Weeks)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 113
- 试验地点
- 30
- 主要终点
- The Proportion of Patients Achieving Undetectable Viral Loads at Week 24.
研究概览
简要总结
The investigational product, ibalizumab, is a humanized IgG4 monoclonal antibody administered via intravenous infusion at 800 mg every 2 weeks or at 2000 mg every 4 weeks. In addition to study drug, all patients will receive an optimized background regimen (OBR), which is a standard-of-care regimen selected by the investigator prior to randomization that is comprised of 2-4 antiretroviral agents. These agents must have been approved by the local regulatory agency or be available through expanded-access programs for treatment of human immunodeficiency virus (HIV).
详细描述
The primary objectives of this study are to:
- Evaluate the dose-response relationship of antiviral activity of the ibalizumab dose regimens at Week 24 in order to determine the optimal dose and regimen. The primary evaluation of effectiveness will be based on the proportion of patients achieving undetectable viral loads at Week 24.
- Evaluate the safety and tolerability of two dose regimens of ibalizumab for dose selection
The secondary objectives of this study are to:
- Evaluate changes from Baseline in viral load, CD4+ cell counts, and time to loss of virologic response (TLOVR)
- Characterize HIV-1 sensitivity/susceptibility changes associated with ibalizumab administration in combination with OBR
- Determine the presence and significance of anti-ibalizumab antibodies, if any (immunogenicity of ibalizumab)
- Assess CD4 receptor density and occupancy
- Determine the impact of ibalizumab on quality of life as assessed by patient-reported outcomes on questionnaires
- Evaluate the pharmacokinetic profile of two dose regimens of ibalizumab at steady state
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Are capable of understanding and have voluntarily signed the informed consent document
- •Have documented HIV-1 infection by official, signed, written history (eg, laboratory report), otherwise an HIV-antibody test will be performed
- •Have no acquired immunodeficiency syndrome (AIDS)-defining events in the 3 months before screening, other than cutaneous Kaposi's sarcoma or wasting syndrome due to HIV
- •Are able and willing to comply with all protocol requirements and procedures
- •Are 18 years of age or older
- •Have a life expectancy that is >6 months.
- •Have a viral load >1,000 copies/mL and documented decreased susceptibility to at least one NRTI, one NNRTI, and one PI, as measured by resistance testing
- •Are receiving a stable highly active antiretroviral regimen for at least 8 weeks before screening and are willing to continue that regimen until the baseline visit, OR (in the past 8 weeks) have failed and are off therapy and are willing to stay off therapy until the baseline visit
- •Have viral sensitivity/susceptibility to at least one agent (OSS criteria) as determined by the screening resistance tests and be willing and able to be treated with at least one agent to which the patient's viral isolate is sensitive/susceptible according to the screening resistance tests as a component of OBR
- •If sexually active, are willing to use an effective method of contraception during the study and for 30 days after the last administration of the study drug
排除标准
- •Any active AIDS-defining illness per Category C conditions according to the Center for Disease Control (CDC) Classification System for HIV Infection, with the following exceptions: cutaneous Kaposi's sarcoma and wasting syndrome due to HIV
- •Any significant diseases (other than HIV-1 infection) or clinically significant findings, including psychiatric and behavioral problems, determined from screening, medical history and/or physical examination that, in the investigator's opinion, would preclude the patient from participating in this study
- •Any significant acute illness within 1 week before the initial administration of study drug
- •Any active infection secondary to HIV requiring acute therapy; however, patients that require maintenance therapy (ie, secondary prophylaxis for opportunistic infections) will be eligible for the study
- •Any immunomodulating therapy (including interferon), systemic steroids, or systemic chemotherapy within 12 weeks before randomization
- •Any investigational therapy within 30 days before randomization, except for HIV-agents available in expanded-access programs
- •Any prior exposure to ibalizumab (formerly TNX-355 and Hu5A8)
- •Any vaccination within 21 days before randomization
- •Any female patient who either is pregnant, intends to become pregnant, or is currently breast-feeding
- •Any current alcohol or illicit drug use that, in the investigator's opinion, will interfere with the patient's ability to comply with the study schedule and protocol evaluations
- •Any previous clinically significant allergy or hypersensitivity to any excipient in the ibalizumab formulation
- •Any radiation therapy during the 28 days before first administration of investigational medication
- •Any grade 3 or 4 toxicity according to the Division of AIDS grading scale, except for the following asymptomatic grade 3 events: triglyceride elevation & total cholesterol elevation
研究组 & 干预措施
Ibalizumab 800 mg
Active Comparator
every 2 weeks, combined with an Optimized Background Regimen
干预措施: Ibalizumab (Drug)
Ibalizumab 2000 mg
Active Comparator
every 4 weeks, combined with an Optimized Background Regimen
干预措施: Ibalizumab (Drug)
结局指标
主要结局
The Proportion of Patients Achieving Undetectable Viral Loads at Week 24.
时间窗: 24 weeks
For the primary efficacy analysis, "undetectable" was defined as having HIV-1 RNA below the limit of assay detection at \<50 copies/mL. The primary efficacy endpoint was analyzed using Fisher exact test. The primary analysis was performed using the ITT population and both the missing data equals treatment failure (MEF) and last observation carried forward (LOCF) methods. The more conservative MEF results are recorded here.
次要结局
- Mean Change From Baseline in Viral Load (log10) at Week 24/EOS(Week 24 / End of Study)
- Mean Change From Baseline in CD4+ T-Cell Count at Week 24/EOS(Week 24 / End of Study)
研究者
研究点 (30)
Loading locations...
相似试验
已完成
1 期
Safety, Efficacy and Pharmacokinetics of an Antibody for Psoriatic ArthritisPsoriatic ArthritisNCT00051662XOMA (US) LLC45
已完成
1 期
A Clinical Trial of Antibody GSK1070806 in the Treatment of Patients With Moderate to Severe Crohn's DiseaseCrohn DiseaseNCT03681067University of Birmingham5
已完成
2 期
IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC)Hepatocellular Carcinoma (HCC)NCT03753659Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest30
已完成
3 期
A Safety and Efficacy Study of Mepolizumab in Subjects With Severe AsthmaAsthmaNCT03562195GlaxoSmithKline300
招募中
1 期
Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) CancerGastric Cancer Stage IVNCT04592211Yonsei University71